Recursion Pharmaceuticals, Inc. Class A RXRX 深 沪
等待开盘 01-20 09:30:00 美东时间
4.67
+0.030
+0.65%
华盛通- 最 高4.88
- 今 开4.65
- 成交量 2141.99万股
- 最 低 4.55
- 昨 收 4.64
- 总市值 20.27亿
- 52周最高 12.36
- 市盈率 静 --
- 换手率 4.94%
- 52周最低 3.79
- 委 比 -6.88%
- 总股本 4.34亿
- 历史最高 42.81
- 量 比 1.13
- 振 幅 7.11%
- 历史最低 3.79
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Most and least shorted large-cap stocks
Short interest across mid- to mega-cap stocks highlights a sharp divide in investor sentiment, with some names drawing heavy bearish bets while others face almost no short pressure at all. The list ou...
01-16 23:05
Recursion Updates AI Drug Platform, Financial Outlook at JPM
Recursion Pharmaceuticals ( ($RXRX) ) just unveiled an announcement. On January...
01-12 21:58
美股夜盘 | Classover Holdings, Inc. Class B涨8.64%，PMGC Holdings Inc.涨8.26%
Faraday Future Intelligent Electric涨-4.88%；Wearable Devices Ltd.涨-3.28%；22nd Century Group, Inc.涨-3.01%
01-08 09:13
2026年展望 | 下一轮机会在哪？港美市场四大前沿投资主题曝光！39家精选企业一文速睇
下一轮机会在哪？英伟达、谷歌争相入局，港美市场四大前沿投资主题曝光！39家精选企业一文速睇>>
01-06 11:44
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-02 01:35
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
XOMA Royalty Corporation and Takeda have amended their 2006 collaboration, reducing Takeda’s royalty and milestone payments for mezagitamab while granting XOMA Royalty payments tied to nine development-stage assets in Takeda’s externalized portfolio. This move diversifies XOMA’s portfolio across early- and late-stage programs, balancing risk and opportunity.
2025-12-30 12:30
3 Small AI Plays to Buy for 2026
Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI stocks for 2026.
2025-12-27 02:28
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10.
2025-12-18 02:06
Recursion jumps as J.P. Morgan upgrades on lead program
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for th...
2025-12-17 23:22
